|
Hybrigenics discovery platform combines and integrates advanced, proprietary technologies that allow us to identify drug targets with a demonstrable role in specific cancer pathways. More specifically, Hybrigenics analyses cancer-relevant biological networks of interacting proteins and conducts cell-based phenotypic screens using functional genetic approaches to identify, select and validate novel cancer targets.
These protein targets are then exploited by the Company to identify and develop small-molecule drug candidates using target class-specific approaches and technologies.
Hybrigenics’ expertise operates at key steps of the Preclinical Research chain, from target discovery to drug candidate selection including:
> Advanced disease-relevant, cellular phenotypic assays and interference technologies,
> High-throughput protein interaction mapping, protein networks and pathways analysis ,
> HTS-compatible, biochemical and cellular screening assays,
> Drug-like, small molecule library screening and medicinal chemistry optimization,
> Molecular modelling and 3D structural studies,
> Preclinical evaluation in dedicated cellular and in vivo models.
|
|
|
|
